The science behind statins and fibrates

International Journal of Clinical Practice, Supplement

Volumn , Issue 132, 2002, Pages 11-16

  Fruchart, Jean Charles ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; CONFERENCE PAPER; CONTROLLED STUDY; FATTY ACID OXIDATION; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; LIPID METABOLISM; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL; THROMBOGENESIS;

ANTILIPEMIC AGENTS; APOLIPOPROTEINS; ARTERIOSCLEROSIS; CHOLESTEROL; CHOLESTEROL, HDL; CLOFIBRATE; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NF-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0036775372     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Auboeuf D, Rieusset J, Fajas L et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: No alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997; 46(8): 1319-1327.
2. Staels B, Koenig W, Habib A et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998; 393(6687): 790-793.
3. Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996; 1302(2): 93-109.
4. Schultz JR, Verstuyft JG, Gong EL et al. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature 1993; 365(6448): 762-764.
5. Vu-Dac N, Schoonjans K, Kosykh V et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 1995; 96(2): 741-750.
6. Berthou L, Duverger N, Emmanuel F et al. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest 1996; 97(11): 2408-2416.
7. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996; 15(19): 5336-5348.
8. Tall AR. An overview of reverse cholesterol transport. Eur Heart J 1998; 19(Suppl A): A31-A35.
9. Chinetti G, Gbaguidi FG, Griglio S et al. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000; 101(20): 2411-2417.
10. Chinetti G, Lestavel S, Bocher V et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Med 2001; 7(1): 53-58.
11. Staels B, Dallongeville J, Auwerx J et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98(19): 2088-2093.
12. Auwerx J, Schoonjans K, Fruchart JC et al. Regulation of triglyceride metabolism by PPARs: Fibrates and thiazolidinediones have distinct effects. J Atheroscler Thromb 1996; 3(2): 81-89.
13. Pennacchio LA, Olivier M, Hubacek JA et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001; 294(5540): 169-173.
14. Inoue I, Shino K, Noji S at al. Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun 1998; 246(2): 370-374.
15. Ricote M, Huang J, Fajas L et al. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 1998; 95(13): 7614-7619.
16. Delerive P, Gervois P, Fruchart JC et al. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 2000; 275(47): 36703-36707.
17. Gervois P, Vu-Dac N, Kleemann R et al. Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta. J Biol Chem 2001; 276(36): 33471-33477.
18. Neve BP, Corseaux D, Chinetti G et al. PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 2001; 103(2): 207-212.
19. Delerive P, Martin-Nizard F, Chinetti G et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999; 85(5): 394-402.
20. Gan X, Kaplan R, Menke JG et al. Dual mechanisms of ABCA1 regulation by geranylgeranyl pyrophosphate. J Biol Chem 2001; 276(52): 48702-48708.
21. Schaefer JR, Schweer H, Ikewaki K et al. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis 1999; 144(1): 177-184.
22. Martin G, Duez H, Blanquart C et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 2001; 107(11): 1423-1432.